C:\Program Files\Stnexp\Queries\10724179.str





chain nodes :
11 12 13 14
ring nodes :
1 2 3 4 5 6 7
ring/chain nodes :
8 9 10
chain bonds :
1-8 10-11 11-12 12-13 13-14
ring/chain bonds :
8-9 9-10
ring bonds :
1-2 1-7 2-3 3-4 4-5 5-6 6-7
exact/norm bonds :
1-2 1-7 1-8 2-3 3-4 4-5 5-6 6-7 8-9 9-10 10-11 12-13 13-14
exact bonds :
11-12

G1:C,O

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:Atom
Generic attributes :
14:
Saturation : Unsaturated
Type of Ring System : Monocyclic

```
=> d his

     (FILE 'HOME' ENTERED AT 15:11:38 ON 04 MAY 2006)

     FILE 'REGISTRY' ENTERED AT 15:11:43 ON 04 MAY 2006
L1             STRUCTURE UPLOADED
L2               3 S L1
L3             226 S L1 SSS FUL
L4             192 S L3 AND 6-6-7/SZ
L5              34 S L3 NOT L4

     FILE 'CAPLUS' ENTERED AT 15:13:34 ON 04 MAY 2006
L6              11 S L4

=> d l1
L1 HAS NO ANSWERS
L1                STR
```



G1 C,O

Structure attributes must be viewed using STN Express query preparation.

=> d ibib abs hitstr total

L6 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:971921 CAPLUS
DOCUMENT NUMBER: 140:19879
TITLE: Drug compositions containing calcium channel antagonists exhibiting intestinal tract selectivity
INVENTOR(S): Hashimoto, Masaki; Takahashi, Kazuyoshi
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan
SOURCE: PCT Int. Appl., 126 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003101490	A1	20031211	WO 2003-JP6847	20030530
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2005343790	A2	20051215	JP 2002-160187	20020531
AU 2003241991	A1	20031219	AU 2003-241991	20030530
PRIORITY APPLN. INFO.:			JP 2002-160187 A	20020531
			WO 2003-JP6847 W	20030530

OTHER SOURCE(S): MARPAT 140:19879

AB Disclosed are a drug composition comprising a calcium channel antagonist exhibiting intestinal tract selectivity that is used for treating Alzheimer disease, mental illness, adolescent insanity, manic depression, migraine, lactation disorder, dementia, autism, hypertension, glaucoma, pain, thromboembolism, arrhythmia, epilepsy or obesity; and a serotonin liberation inhibitor comprising a calcium channel antagonist exhibiting intestinal tract selectivity. A compound (R)-3-chloro-5,11-dihydro-5-[1-(4-dimethylaminophenethyl)pyrrolidine-2-ylmethyl]dibenzo[b,e][1,4]oxazepine dihydrochloride (I) was prepared, and its effect on serotonin liberation in isolated mouse ileum was tested. A tablet containing I 50 mg/tablet was also formulated.

IT **477778-65-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(medicinal compns. containing calcium channel antagonists exhibiting intestinal tract selectivity)

RN 477778-65-7 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-[(3-chlorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

IT **477778-53-3P 477778-55-5P 477778-57-7P**
477778-61-3P 477778-63-5P 477778-69-1P
477778-71-5P 477778-73-7P 477778-75-9P
477778-77-1P 477778-79-3P 477778-81-7P
477778-83-9P 477778-85-1P 477778-91-9P
477778-93-1P 477778-95-3P 477778-97-5P
630095-00-0P 630095-01-1P 630095-02-2P
630095-03-3P 630095-04-4P 630095-05-5P
630095-06-6P 630095-07-7P 630095-08-8P
630095-09-9P 630095-10-2P 630095-11-3P
630095-13-5P 630095-14-6P 630095-15-7P
630095-16-8P 630095-17-9P 630095-18-0P
630095-19-1P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(medicinal compns. containing calcium channel antagonists exhibiting intestinal tract selectivity)

RN 477778-53-3 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 8-fluoro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-55-5 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 2-chloro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-57-7 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 477778-61-3 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-[(1-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-63-5 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-[(3-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-69-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-71-5 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 7-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-73-7 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 8-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-75-9 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-77-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-79-3 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-[4-(4-morpholinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-81-7 CAPLUS
CN Benzenamine, 4-[2-[(3R)-3-(2-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-83-9 CAPLUS
CN Benzenamine, 4-[2-[(3R)-3-(3-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-85-1 CAPLUS
CN Benzenamine, 4-[2-[(3R)-3-(3-chlorodibenz[b,e][1,4]oxazepin-5(11H)-yl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-91-9 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-93-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[(3R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-3-pyrrolidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-95-3 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[(3R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-3-pyrrolidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-97-5 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-methyl-N-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 630095-00-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-fluoro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 630095-01-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 7-chloro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 630095-02-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 2-fluoro-5,11-dihydro-5-[[(2R)-1-[2-(3-pyridinyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 630095-03-3 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-(5-pyrimidinyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 630095-04-4 CAPLUS
CN Pyrido[2,3-b][4,1]benzoxazepine, 6,11-dihydro-11-[[(2R)-1-[2-[5-(1-pyrrolidinyl)pyrazinyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 630095-05-5 CAPLUS
CN Pyrido[3,2-c][1,5]benzoxazepine, 8-fluoro-5,11-dihydro-11-[[(2R)-1-[2-(6-methoxy-3-pyridazinyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 630095-06-6 CAPLUS
CN Pyrido[2,3-b][4,1]benzoxazepine, 9-chloro-6,11-dihydro-11-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 630095-07-7 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-[(3-chloropyrido[2,3-c][1,5]benzoxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 630095-08-8 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 2-fluoro-5,11-dihydro-5-[(3R)-1-[2-(3-pyridinyl)ethyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 630095-09-9 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 8-chloro-5,11-dihydro-5-[(3R)-1-[2-(5-pyrimidinyl)ethyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 630095-10-2 CAPLUS
CN Pyrido[2,3-b][4,1]benzoxazepine, 8-fluoro-6,11-dihydro-11-[(3R)-1-(2-pyrazinylethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 630095-11-3 CAPLUS
CN Pyrido[3,2-c][1,5]benzoxazepine, 8-fluoro-5,11-dihydro-11-[(3R)-1-[2-(5-methoxy-3-pyridazinyl)ethyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 630095-13-5 CAPLUS
CN Pyrido[2,3-c][1,5]benzoxazepine, 3-chloro-5,11-dihydro-5-[(3R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 630095-14-6 CAPLUS
CN Pyrido[2,3-b][4,1]benzoxazepine-11(6H)-ethanamine, N-methyl-N-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 630095-15-7 CAPLUS
CN Pyrido[2,3-c][1,5]benzoxazepine-5(11H)-ethanamine, 3-fluoro-N-[2-(3-methoxyphenyl)ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 630095-16-8 CAPLUS
CN Pyrido[3,2-c][1,5]benzoxazepine-11(5H)-ethanamine, N-methyl-N-[2-[5-(1-pyrrolidinyl)-2-pyrimidinyl]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 630095-17-9 CAPLUS
CN Pyrido[3,2-c][1,5]benzoxazepine-11(5H)-ethanamine, 9-fluoro-N-[2-(2-methoxy-4-pyridinyl)ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 630095-18-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, 3-chloro-N-[2-(5-methoxypyrazinyl)ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 630095-19-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[2-[6-(dimethylamino)-3-pyridinyl]ethyl]-7-fluoro-N-methyl- (9CI) (CA INDEX NAME)



IT **477778-66-8**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicinal compns. containing calcium channel antagonists exhibiting intestinal tract selectivity)
RN 477778-66-8 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-[(3-chlorodibenz[b,e][1,4]oxazepin-5(11H)-

yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **477778-54-4P 477778-56-6P 477778-58-8P**
477778-62-4P 477778-64-6P 477778-68-0P
477778-70-4P 477778-72-6P 477778-74-8P
477778-76-0P 477778-78-2P 477778-80-6P
477778-82-8P 477778-84-0P 477778-86-2P
477778-88-4P 477778-92-0P 477778-96-4P
477778-98-6P 477779-17-2P 477779-22-9P
630095-20-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of calcium channel antagonists exhibiting intestinal tract selectivity)

RN 477778-54-4 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 8-fluoro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-56-6 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 2-chloro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-58-8 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-62-4 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-[(1-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-64-6 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-[(3-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-68-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 2-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-70-4 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-72-6 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 7-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-74-8 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 8-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-76-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-78-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-80-6 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-[4-(4-morpholinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-82-8 CAPLUS
CN Benzenamine, 4-[2-[(3R)-3-(2-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-84-0 CAPLUS
CN Benzenamine, 4-[2-[(3R)-3-(3-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-86-2 CAPLUS
CN Benzenamine, 4-[2-[(3R)-3-(3-chlorodibenz[b,e][1,4]oxazepin-5(11H)-yl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-88-4 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-fluoro-5,11-dihydro-5-[(3R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-92-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-96-4 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[(3R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-98-6 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-methyl-N-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 477779-17-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5-[[(2R)-1-[[4-(dimethylamino)phenyl]acetyl]-2-pyrrolidinyl]carbonyl]-5,11-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477779-22-9 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 2-fluoro-5,11-dihydro-5-[[(2R)-1-[[4-(1-pyrrolidinyl)phenyl]acetyl]-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 630095-20-4 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-fluoro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **477778-94-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of calcium channel antagonists exhibiting intestinal tract selectivity)
RN 477778-94-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[(3R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 98 THERE ARE 98 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:971920 CAPLUS
DOCUMENT NUMBER: 140:19878
TITLE: Medicinal compositions containing defined calcium channel antagonists for treatment for digestive tract disease
INVENTOR(S): Yamada, Youji; Takahashi, Kazuyoshi; Hashimoto, Masaki
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan
SOURCE: PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003101489	A1	20031211	WO 2003-JP6845	20030530
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2005343791	A2	20051215	JP 2002-160188	20020531
AU 2003241987	A1	20031219	AU 2003-241987	20030530
PRIORITY APPLN. INFO.:			JP 2002-160188 A	20020531
			WO 2003-JP6845 W	20030530

OTHER SOURCE(S): MARPAT 140:19878
AB Disclosed is a medicinal composition containing defined calcium channel antagonist,
e.g. 5,11-dihydrodiaryl[b,e][1,4]oxazepine derivative, 5,11-dihydrodibenzo[b,e][1,4]thiazepine derivative, etc., having a selectivity to digestive tract. The composition is used for treatments for diseases accompanied by an organic change of the digestive tract. A compound (R)-3-chloro-5,11-dihydro-5-[1-(4-dimethylaminophenethyl)pyrrolidine-2-ylmethyl]dibenzo[b,e][1,4]oxazepine dihydrochloride (I) was prepared, and its calcium channel blocking effect on isolated colon and ileum membranes. A tablet containing I 50 mg/tablet was also formulated.
IT **477778-65-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(medicinal compns. containing defined calcium channel antagonists for treatment for digestive tract disease)
RN 477778-65-7 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-[(3-chlorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

IT **477778-54-4P 630095-20-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(medicinal compns. containing defined calcium channel antagonists for treatment for digestive tract disease)

RN 477778-54-4 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 8-fluoro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 630095-20-4 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-fluoro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **477778-53-3P 477778-55-5P 477778-57-7P**
477778-61-3P 477778-63-5P 477778-69-1P
477778-71-5P 477778-73-7P 477778-75-9P
477778-77-1P 477778-79-3P 477778-81-7P
477778-83-9P 477778-85-1P 477778-91-9P
477778-93-1P 477778-95-3P 477778-97-5P
630095-00-0P 630095-01-1P 630095-02-2P
630095-03-3P 630095-04-4P 630095-05-5P
630095-06-6P 630095-07-7P 630095-08-8P
630095-09-9P 630095-10-2P 630095-11-3P
630095-13-5P 630095-14-6P 630095-15-7P
630095-16-8P 630095-17-9P 630095-19-1P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(medicinal compns. containing defined calcium channel antagonists for treatment for digestive tract disease)

RN 477778-53-3 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 8-fluoro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 477778-55-5 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 2-chloro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 477778-57-7 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 477778-61-3 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-[(1-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-63-5 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-[(3-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-69-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-71-5 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 7-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-73-7 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 8-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-75-9 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-77-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-79-3 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-[4-(4-morpholinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-81-7 CAPLUS
CN Benzenamine, 4-[2-[(3R)-3-(2-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-83-9 CAPLUS
CN Benzenamine, 4-[2-[(3R)-3-(3-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-85-1 CAPLUS
CN Benzenamine, 4-[2-[(3R)-3-(3-chlorodibenz[b,e][1,4]oxazepin-5(11H)-yl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-91-9 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-93-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[(3R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-3-pyrrolidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-95-3 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[(3R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-3-pyrrolidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-97-5 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-methyl-N-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 630095-00-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-fluoro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 630095-01-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 7-chloro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 630095-02-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 2-fluoro-5,11-dihydro-5-[[(2R)-1-[2-(3-pyridinyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 630095-03-3 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-(5-pyrimidinyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 630095-04-4 CAPLUS
CN Pyrido[2,3-b][4,1]benzoxazepine, 6,11-dihydro-11-[[(2R)-1-[2-[5-(1-pyrrolidinyl)pyrazinyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 630095-05-5 CAPLUS
CN Pyrido[3,2-c][1,5]benzoxazepine, 8-fluoro-5,11-dihydro-11-[[(2R)-1-[2-(6-methoxy-3-pyridazinyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 630095-06-6 CAPLUS
CN Pyrido[2,3-b][4,1]benzoxazepine, 9-chloro-6,11-dihydro-11-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 630095-07-7 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-[(3-chloropyrido[2,3-c][1,5]benzoxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 630095-08-8 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 2-fluoro-5,11-dihydro-5-[(3R)-1-[2-(3-pyridinyl)ethyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 630095-09-9 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 8-chloro-5,11-dihydro-5-[(3R)-1-[2-(5-pyrimidinyl)ethyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 630095-10-2 CAPLUS
CN Pyrido[2,3-b][4,1]benzoxazepine, 8-fluoro-6,11-dihydro-11-[(3R)-1-(2-pyrazinylethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 630095-11-3 CAPLUS
CN Pyrido[3,2-c][1,5]benzoxazepine, 8-fluoro-5,11-dihydro-11-[(3R)-1-[2-(5-methoxy-3-pyridazinyl)ethyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 630095-13-5 CAPLUS
CN Pyrido[2,3-c][1,5]benzoxazepine, 3-chloro-5,11-dihydro-5-[(3R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 630095-14-6 CAPLUS
CN Pyrido[2,3-b][4,1]benzoxazepine-11(6H)-ethanamine, N-methyl-N-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 630095-15-7 CAPLUS
CN Pyrido[2,3-c][1,5]benzoxazepine-5(11H)-ethanamine, 3-fluoro-N-[2-(3-methoxyphenyl)ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 630095-16-8 CAPLUS
CN Pyrido[3,2-c][1,5]benzoxazepine-11(5H)-ethanamine, N-methyl-N-[2-[5-(1-pyrrolidinyl)-2-pyrimidinyl]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 630095-17-9 CAPLUS
CN Pyrido[3,2-c][1,5]benzoxazepine-11(5H)-ethanamine, 9-fluoro-N-[2-(2-methoxy-4-pyridinyl)ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 630095-19-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[2-[6-(dimethylamino)-3-pyridinyl]ethyl]-7-fluoro-N-methyl- (9CI) (CA INDEX NAME)



IT **477778-66-8**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicinal compns. containing defined calcium channel antagonists for treatment for digestive tract disease)
RN 477778-66-8 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-[(3-chlorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **630095-18-0P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(nmedicinal compns. containing defined calcium channel antagonists for

treatment for digestive tract disease)
RN 630095-18-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, 3-chloro-N-[2-(5-methoxypyrazinyl)ethyl]-N-methyl- (9CI) (CA INDEX NAME)



IT **477778-56-6P 477778-58-8P 477778-62-4P**
477778-64-6P 477778-68-0P 477778-70-4P
477778-72-6P 477778-74-8P 477778-76-0P
477778-78-2P 477778-80-6P 477778-82-8P
477778-84-0P 477778-86-2P 477778-88-4P
477778-92-0P 477778-96-4P 477778-98-6P
477779-17-2P 477779-22-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of medicinal compns. containing defined calcium channel antagonists
for treatment for digestive tract disease)
RN 477778-56-6 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 2-chloro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-58-8 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-62-4 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-[(1-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-64-6 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-[(3-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-68-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 2-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-70-4 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-72-6 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 7-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-74-8 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 8-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-76-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-78-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-80-6 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-[4-(4-morpholinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-82-8 CAPLUS
CN Benzenamine, 4-[2-[(3R)-3-(2-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-84-0 CAPLUS
CN Benzenamine, 4-[2-[(3R)-3-(3-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-86-2 CAPLUS
CN Benzenamine, 4-[2-[(3R)-3-(3-chlorodibenz[b,e][1,4]oxazepin-5(11H)-yl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-88-4 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-fluoro-5,11-dihydro-5-[(3R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-92-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-96-4 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[(3R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-98-6 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-methyl-N-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 477779-17-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5-[[(2R)-1-[[4-(dimethylamino)phenyl]acetyl]-2-pyrrolidinyl]carbonyl]-5,11-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477779-22-9 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 2-fluoro-5,11-dihydro-5-[[(2R)-1-[[4-(1-pyrrolidinyl)phenyl]acetyl]-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **477778-94-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of medicinal compns. containing defined calcium channel antagonists
for treatment for digestive tract disease)
RN 477778-94-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[(3R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:927415 CAPLUS
DOCUMENT NUMBER: 138:14080
TITLE: Preparation of dihydrodiaryloxazepine derivatives for treatment of functional digestive tract diseases
INVENTOR(S): Sakata, Katsutoshi; Tsuji, Takashi; Tokumasu, Munetaka; Takahashi, Kazuyoshi; Hirasawa, Shigeo; Ezaki, Junko
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan
SOURCE: PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002096891	A1	20021205	WO 2002-JP5193		20020529
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
EP 1403258	A1	20040331	EP 2002-730742		20020529
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
US 2004110742	A1	20040610	US 2003-724179		20031201
PRIORITY APPLN. INFO.:			JP 2001-161988	A	20010530
			WO 2002-JP5193	W	20020529

OTHER SOURCE(S): MARPAT 138:14080
GI



I

AB The title compds. I [ring G, J, K = benzene ring or N-containing aromatic ring; R1 - R8 = halo, H; R9 - R13 = H, halo, cyano, etc.; A = CH2, etc.; B = CO, etc.; or AB = CH:CH; D = CH2, etc.; or BD = CH2; XZ = CH2CH2, CH2CH2CH2, and Y = H; or YZ = CH2CH2CH2, CH2CH2CH2CH2, and X = H; further detail on X, Y, Z is given; a proviso is given] are prepared Compds. of this invention are calcium channel antagonists with selectivity for the intestinal tract (IC50 values of 5.6 nM to 82.5 nM) and are useful in the treatment of functional digestive tract diseases. Formulations are given.

IT **195991-49-2P 195991-50-5P 477778-53-3P**
477778-54-4P 477778-55-5P 477778-56-6P
477778-57-7P 477778-58-8P 477778-61-3P
477778-62-4P 477778-63-5P 477778-64-6P
477778-65-7P 477778-66-8P 477778-67-9P
477778-68-0P 477778-69-1P 477778-70-4P
477778-71-5P 477778-72-6P 477778-73-7P
477778-74-8P 477778-75-9P 477778-76-0P
477778-77-1P 477778-78-2P 477778-79-3P
477778-80-6P 477778-81-7P 477778-82-8P
477778-83-9P 477778-84-0P 477778-85-1P
477778-86-2P 477778-87-3P 477778-88-4P
477778-89-5P 477778-90-8P 477778-91-9P
477778-92-0P 477778-93-1P 477778-94-2P
477778-95-3P 477778-96-4P 477778-97-5P
477778-98-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of dihydrodiaryloxazepine derivs. for treatment of functional digestive tract diseases)

RN 195991-49-2 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 195991-50-5 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 477778-53-3 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 8-fluoro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-54-4 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 8-fluoro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-55-5 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 2-chloro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 477778-56-6 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 2-chloro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-57-7 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 477778-58-8 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-61-3 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-[(1-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-62-4 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-[(1-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-63-5 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-[(3-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 477778-64-6 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-[(3-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-65-7 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-[(3-chlorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-66-8 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-[(3-chlorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-67-9 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 2-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-68-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 2-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-69-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-70-4 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-71-5 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 7-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-72-6 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 7-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-73-7 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 8-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI)

(CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-74-8 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 8-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-75-9 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-

pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-76-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-77-1 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-78-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-79-3 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-[4-(4-morpholinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-80-6 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-[4-(4-morpholinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-81-7 CAPLUS
CN Benzenamine, 4-[2-[(3R)-3-(2-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-82-8 CAPLUS
CN Benzenamine, 4-[2-[(3R)-3-(2-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-83-9 CAPLUS
CN Benzenamine, 4-[2-[(3R)-3-(3-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-84-0 CAPLUS
CN Benzenamine, 4-[2-[(3R)-3-(3-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-85-1 CAPLUS
CN Benzenamine, 4-[2-[(3R)-3-(3-chlorodibenz[b,e][1,4]oxazepin-5(11H)-yl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-86-2 CAPLUS
CN Benzenamine, 4-[2-[(3R)-3-(3-chlorodibenz[b,e][1,4]oxazepin-5(11H)-yl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-87-3 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-fluoro-5,11-dihydro-5-[(3R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-3-pyrrolidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-88-4 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-fluoro-5,11-dihydro-5-[(3R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-89-5 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[(3R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-3-pyrrolidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-90-8 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[(3R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-91-9 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-92-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-93-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[(3R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-3-pyrrolidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-94-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[(3R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-95-3 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[(3R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-3-pyrrolidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-96-4 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[(3R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-97-5 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-methyl-N-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 477778-98-6 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-methyl-N-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)



IT **477779-17-2P 477779-22-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of dihydrodiaryloxazepine derivs. for treatment of functional digestive tract diseases)

RN 477779-17-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5-[[(2R)-1-[[4-(dimethylamino)phenyl]acetyl]-2-pyrrolidinyl]carbonyl]-5,11-dihydro- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.



RN 477779-22-9 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 2-fluoro-5,11-dihydro-5-[[(2R)-1-[[4-(1-pyrrolidinyl)phenyl]acetyl]-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:465986 CAPLUS
DOCUMENT NUMBER: 137:33327
TITLE: Process for preparing crystals of oxazepine derivatives
INVENTOR(S): Matsuzawa, Toshihiro; Sekiyama, Takaaki; Yatagai, Masanobu
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002048120	A1	20020620	WO 2000-JP8739	20001211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001017359	A5	20020624	AU 2001-17359	20001211
PRIORITY APPLN. INFO.:			WO 2000-JP8739	A 20001211

OTHER SOURCE(S): CASREACT 137:33327

AB This document discloses a process which comprises dissolving in a solvent a mixture of optically active 5,11-dihydro-5-[1-(4-methoxyphenethyl)-2-pyrrolidinylmethyl]dibenzo[b,e][1,4]oxazepine (I) with optically active 5,11-dihydro-5-[1-[2-(4-methoxyphenyl)ethyl]piperidin-3-yl]dibenzo[b,e][1,4]oxazepine, adding nitric acid to the obtained solution to precipitate crystals, and separating these crystals from the resulting system. I is a known calcium antagonist for the treatment of irritable bowel syndrome.

IT **437703-60-1P**
RL: BYP (Byproduct); PREP (Preparation)
(optically active, unspecified; process for preparing crystals of oxazepine derivs.)

RN 437703-60-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[1-[2-(4-methoxyphenyl)ethyl]-3-piperidinyl]- (9CI) (CA INDEX NAME)



IT **437703-58-7P**
RL: BYP (Byproduct); PREP (Preparation)
(process for preparing crystals of oxazepine derivs.)
RN 437703-58-7 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[(3S)-1-[2-(4-methoxyphenyl)ethyl]-3-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **195991-49-2P 195991-50-5P 313048-22-5P**
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(process for preparing crystals of oxazepine derivs.)
RN 195991-49-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 195991-50-5 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 313048-22-5 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, mononitrate (9CI) (CA INDEX NAME)

CM 1

CRN 195991-49-2
CMF C27 H30 N2 O2

Absolute stereochemistry. Rotation (+).



CM 2

CRN 7697-37-2
CMF H N O3



IT **437703-61-2P 437703-62-3P 437703-63-4P**
RL: PUR (Purification or recovery); SPN (Synthetic preparation); PREP (Preparation)
(process for preparing crystals of oxazepine derivs.)

RN 437703-61-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 437703-62-3 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, mononitrate (9CI) (CA INDEX NAME)

CM 1

CRN 437703-61-2
CMF C27 H30 N2 O2



CM 2

CRN 7697-37-2
CMF H N O3



RN 437703-63-4 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:185738 CAPLUS
DOCUMENT NUMBER: 134:222732
TITLE: Novel processes for preparing oxazepine derivatives via cyclization of 2-(2-bromobenzyloxy)aniline derivative
INVENTOR(S): Sekiyama, Takaaki; Matsuzawa, Toshihiro; Yamamoto, Takashi; Yatagai, Masanobu; Ezaki, Junko
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001017980	A1	20010315	WO 2000-JP5967	20000901
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000068689	A5	20010410	AU 2000-68689	20000901
EP 1219611	A1	20020703	EP 2000-956884	20000901
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
US 2002133004	A1	20020919	US 2002-86781	20020304
PRIORITY APPLN. INFO.:			JP 1999-250298 A	19990903
			WO 2000-JP5967 W	20000901

OTHER SOURCE(S): CASREACT 134:222732; MARPAT 134:222732
GI



AB Industrially advantageous processes for preparing 5-substituted-5,11-dihydrodibenz[b,e][1,4]oxazepine derivs. (I; Z = CH2: Y1 = H; Y2 = H, lower alkyl; or Y1 and Y2 together represent (CH2)3 or (CH2)4; Y3 = CH2, CH2CH2; R1 - R5 = H, halo, lower alkyl, HO, lower alkoxy, NH2, lower alkylamino; or R1 and R2, R2 and R3, R3 and R4, or R4 and R5 together represents OCH2O) through intramol. arylation and reduction from [2-(2-bromobenzyloxy)phenyl]amide derivs. bearing via amide linkage substituents to be introduced at the 5-position are described. More particularly, a process comprises subjecting (R)-1-[(4-methoxyphenyl)acetyl]pyrrolidine-2-carboxylic [2-(2-bromobenzyloxy)phenyl]amide (II; Y1- Y3, R1-R5 = same as above) to intramol. arylation to form (R)-[[2-(5,11-dihydrodibenz[b,e][1,4]oxazepine-5-carbonyl)pyrrolidin]-1-yl]-2-(4-methoxyphenyl)ethanone I (Z = CO; Y1-Y3, R1-R5 = same as above) and then reducing the obtained compound The compds. I possesses calcium channel antagonism and are useful for the prevention or treatment of digestive tract motility disorders, in particular intestinal disorders such as irritable bowel syndrome. Thus, (R)-1-[(4-methoxyphenyl)acetyl]pyrrolidine-2-carboxylic acid [2-(2-bromobenzyloxy)phenyl]amide (preparation given) (1.69 kg), 23.0 g CuBr, and 443 g K2CO3 were added to 4.19 L pyridine and heated under reflux for 100 h to give, after workup and silica gel chromatog., 1.35 kg (R)-[2-[(5,11-dihydrodibenzo[b,e][1,4]oxazepin-5-yl)carbonyl]pyrrolidin-1-yl]-2-(4-methoxyphenyl)ethanone (95% yield). A solution of the latter compound (1.35 kg) in 2.69 L THF was added to a cooled (5°) suspension of 400 g NaBH4 in 19.77 L THF, treated dropwise with 1.97 kg BF3-THF complex at ≤10°, stirred at 5° for 1 h and 40° for 14 h, cooled at 5°, treated dropwise with 13.6 L 1.5 M aqueous NaOH, and stirred at 60° for 2 h. The reaction mixture was extracted with 8.1 L PhMe and the organic layer was concentrated in vacuo to .apprx.7.5 L, washed with water three times, warmed at 30°, treated dropwise with 941 L 4 M HCl/EtOAc, stirred at 5° overnight, and filtered to collect precipitated crystals which ere recrystd. from 2-propanol to give 1.00 kg (R)-(+)-5,11-dihydro-5-[1-(4-methoxyphenethyl)-2-pyrrolidinylmethyl]dibenzo[b,e][1,4]oxazepine hydrochloride (73%).

IT **329329-18-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(novel processes for preparing oxazepine derivs. via cyclization of (bromobenzyloxy)aniline derivative)

RN 329329-18-2 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[(4-methoxyphenyl)acetyl]-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **195991-50-5P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(novel processes for preparing oxazepine derivs. via cyclization of (bromobenzyloxy)aniline derivative)

RN 195991-50-5 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:889402 CAPLUS
DOCUMENT NUMBER: 134:42148
TITLE: Preparation of crystals of oxazepines for treatment of irritable colon syndrome
INVENTOR(S): Matsusawa, Toshihiro; Sekiyama, Takaaki; Yatagai, Masanobu
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000351778	A2	20001219	JP 1999-162760	19990609
PRIORITY APPLN. INFO.:			JP 1999-162760	19990609

OTHER SOURCE(S): CASREACT 134:42148

AB 5,11-Dihydro-5-[1-(4-methoxyphenethyl)-2-pyrrolidinylmethyl]dibenzo[b,e][1,4]oxazepine nitrate (I), useful treatment of irritable colon syndrome, etc. (no data), is prepared by reaction of 5,11-dihydrodibenzo[b,e][1,4]oxazepine with optically active 3-chloro-1-(4-methoxyphenethyl)piperidine, reaction of the resulting mixts. containing optically active 5,11-dihydro-5-[1-(4-methoxyphenethyl)-2-pyrrolidinylmethyl]dibenzo[b,e][1,4]oxazepine (II) and 5,11-dihydro-5-[1-[2-(4-methoxyphenyl)ethyl]piperidin-3-yl]dibenzo[b,e][1,4]oxazepine (III) in HNO3 in solvents, and isolation of I by crystallization 5,11-Dihydrodibenzo[b,e][1,4]oxazepine was reacted with (S)-(+)-3-chloro-1-(4-methoxyphenethyl)piperidine in the presence of NaH in DMSO at 50° for 5 h to give 7.3:1 mixture of (R)-(+)-II and (S)-III, which was reacted with HNO3 in EtOH at room temperature overnight to give 43.7% (R)-I.

IT **195991-49-2P**
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of crystals of oxazepines by condensation of benzooxazepine with chloropiperidine and reaction with nitric acid)

RN 195991-49-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **313048-22-5P**
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of crystals of oxazepines by condensation of benzooxazepine with chloropiperidine and reaction with nitric acid)

RN 313048-22-5 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, mononitrate (9CI) (CA INDEX NAME)

CM 1

CRN 195991-49-2
CMF C27 H30 N2 O2

Absolute stereochemistry. Rotation (+).



CM 2

CRN 7697-37-2
CMF H N O3



IT **195991-50-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of crystals of oxazepines by condensation of benzooxazepine with chloropiperidine and reaction with nitric acid)
RN 195991-50-5 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L6 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:475653 CAPLUS
DOCUMENT NUMBER: 133:89556
TITLE: Preparation of oxazepine derivatives and drugs containing the same
INVENTOR(S): Sakata, Katsutoshi; Tsuji, Takashi; Sasaki, Noriko; Takahashi, Kazuyoshi
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan
SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000040570	A1	20000713	WO 2000-JP71	20000111
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1142884	A1	20011010	EP 2000-900167	20000111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EP 1471060	A1	20041027	EP 2004-14975	20000111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
EP 1475373	A1	20041110	EP 2004-14974	20000111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
US 2002099047	A1	20020725	US 2001-899928	20010709
US 6528504	B2	20030304		

PRIORITY APPLN. INFO.:		
JP 1999-3268	A	19990108
JP 1999-3269	A	19990108
JP 1999-3270	A	19990108
EP 2000-900167	A3	20000111
WO 2000-JP71	W	20000111

OTHER SOURCE(S): MARPAT 133:89556
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. [I; A = Q, Q1, Q2; R = H, Cl, (CH3)2N, CH3O; R1 = CH3O, N(CH3)2, H; R-R1 = OCH2O; n = 2, 3;], salts, stereoisomers, and drug compns. containing I are prepared and are useful in the treatment or prevention of motor function disorder of digestive tract, particularly intestinal diseases including irritable bowel syndrome. Thus, the title compds. (R)-5,11-Dihydro-5-[1-(4-methoxyphenethyl)-piperidin-2-ylmethyl]dibenzo[b,e][1,4] oxazepine and (R)-5,11-dihydro-5-[1-(4-dimethylaminophenethyl)-piperidin-2-ylmethyl]dibenzo[b, e][1,4]oxazepin

were prepared and tested.

IT **281677-32-5P 281677-34-7P 281677-35-8P**
281677-37-0P 281677-38-1P 281677-39-2P
281677-41-6P 281677-42-7P 281677-44-9P
281677-45-0P 281677-46-1P 281677-47-2P
281677-49-4P 281677-50-7P 281677-51-8P
281677-52-9P 281677-53-0P 281677-54-1P
281677-55-2P 281677-56-3P 281677-57-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazepine derivs. and drugs containing the same)

RN 281677-32-5 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 281677-34-7 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2S)-1-[2-(3-methoxyphenyl)ethyl]-2-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 281677-35-8 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[3-(4-methoxyphenyl)propyl]-2-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 281677-37-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[[(2R)-1-[2-(4-chlorophenyl)ethyl]-2-piperidinyl]methyl]-5,11-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 281677-38-1 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-piperidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 281677-39-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[(3R)-1-[2-(4-methoxyphenyl)ethyl]-3-pyrrolidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 281677-41-6 CAPLUS
CN Benzenamine, 4-[2-[(3R)-3-dibenz[b,e][1,4]oxazepin-5(11H)-yl-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 281677-42-7 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[(3R)-1-[3-(4-methoxyphenyl)propyl]-3-pyrrolidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 281677-44-9 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[(3R)-1-[2-(4-chlorophenyl)ethyl]-3-pyrrolidinyl]-5,11-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 281677-45-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[2-(4-methoxyphenyl)ethyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



RN 281677-46-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[2-(3-methoxyphenyl)ethyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



RN 281677-47-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[3-(4-methoxyphenyl)propyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



RN 281677-49-4 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[2-(4-chlorophenyl)ethyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



RN 281677-50-7 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[2-[4-(dimethylamino)phenyl]ethyl]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 281677-51-8 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[2-[3-(dimethylamino)phenyl]ethyl]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 281677-52-9 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 281677-53-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2S)-1-[2-(3-methoxyphenyl)ethyl]-2-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 281677-54-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[(3R)-1-[2-(4-methoxyphenyl)ethyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 281677-55-2 CAPLUS
CN Benzenamine, 4-[2-[(3R)-3-dibenz[b,e][1,4]oxazepin-5(11H)-yl-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 281677-56-3 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[2-(4-methoxyphenyl)ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 281677-57-4 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[2-(3-methoxyphenyl)ethyl]-N-methyl- (9CI) (CA INDEX NAME)



IT **281677-61-0P 281677-64-3P 281677-70-1P**
281677-73-4P 281677-85-8P 281677-93-8P
281678-00-0P 281678-02-2P 281678-03-3P
281678-04-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of oxazepine derivs. and drugs containing the same)

RN 281677-61-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-(3-methoxyphenyl)ethyl]-2-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 281677-64-3 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[3-(4-methoxyphenyl)propyl]-2-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 281677-70-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[[(2R)-1-[2-(4-chlorophenyl)ethyl]-2-piperidinyl]methyl]-5,11-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 281677-73-4 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-piperidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 281677-85-8 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[(3R)-1-[3-(4-methoxyphenyl)propyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 281677-93-8 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[(3R)-1-[2-(4-chlorophenyl)ethyl]-3-pyrrolidinyl]-5,11-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 281678-00-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[3-(4-methoxyphenyl)propyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 281678-02-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[2-(4-chlorophenyl)ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 281678-03-3 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[2-[4-(dimethylamino)phenyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 281678-04-4 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[2-[3-(dimethylamino)phenyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)



IT **281677-33-6P 281677-40-5P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazepine derivs. and drugs containing the same)
RN 281677-33-6 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2S)-1-[2-(4-methoxyphenyl)ethyl]-2-piperidinyl]methyl]-, monohydrochloride (9CI) (CA

INDEX NAME)

Absolute stereochemistry.



● HCl

RN 281677-40-5 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[(3S)-1-[2-(4-methoxyphenyl)ethyl]-3-pyrrolidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:194140 CAPLUS
DOCUMENT NUMBER: 130:223305
TITLE: Preparation and formulation of 5,11-dihydrodibenz[b,e][1,4]oxazepine derivatives as calcium antagonists
INVENTOR(S): Sakata, Katsutoshi; Tsuji, Takashi; Sasaki, Noriko; Takahashi, Kazuyoshi
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9912925	A1	19990318	WO 1998-JP4071	19980910
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2304262	AA	19990318	CA 1998-2304262	19980910
AU 9890014	A1	19990329	AU 1998-90014	19980910
AU 740878	B2	20011115		
EP 1020466	A1	20000719	EP 1998-941803	19980910
EP 1020466	B1	20030219		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
AT 232861	E	20030315	AT 1998-941803	19980910
US 6562808	B1	20030513	US 2000-522946	20000310
PRIORITY APPLN. INFO.:			JP 1997-245669 A	19970910
			JP 1997-245670 A	19970910
			WO 1998-JP4071 W	19980910

OTHER SOURCE(S): MARPAT 130:223305
GI



I

AB The title compds. I [R1 - R5 = H, alkoxy, etc.; R6, R7 = H, hydroxy; Y1 = methylene, etc.] are prepared I are useful in the treatment or prevention of intestinal diseases such as gastrointestinal tract dyskinesia, in particular, irritable bowel syndrome. In an in vitro test for calcium antagonism using ileum, (R)-5,11-Dihydro-5-[1-[2-(4-dimethylaminophenyl)ethyl]-2-pyrrolidinylmethyl]dibenzo[b,e][1,4]oxazepine dihydrochloride (II) in vitro showed IC50 of 35 nM; in an in vitro test for calcium antagonism using artery, II showed IC50 of 255 nM. I also showed high water solubility

IT **221159-49-5P 221159-53-1P 221159-56-4P**
221159-60-0P 221159-63-3P 221159-66-6P
221159-69-9P 221159-72-4P 221159-75-7P
221159-77-9P 221159-80-4P 221159-84-8P
221159-91-7P 221159-97-3P 221160-01-6P
221160-05-0P 221160-09-4P 221160-13-0P
221160-22-1P 221160-29-8P 221160-36-7P
221160-44-7P 221160-51-6P 221160-58-3P
221160-64-1P 221160-70-9P 221160-75-4P
221160-82-3P 221160-86-7P 221160-90-3P
221160-94-7P 221160-99-2P 221161-03-1P
221161-07-5P 221161-10-0P 221161-13-3P
221161-14-4P 221161-15-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of dihydrodibenzoxazepine derivs. as calcium antagonists)

RN 221159-49-5 CAPLUS

CN Benzenamine, 4-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221159-53-1 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 221159-56-4 CAPLUS
CN Benzenamine, 4-[2-[(2S)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221159-60-0 CAPLUS
CN Benzenamine, 4-[2-[(2S)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221159-63-3 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N,N-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221159-66-6 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 221159-69-9 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221159-72-4 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 221159-75-7 CAPLUS
CN Benzenamine, 3-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221159-77-9 CAPLUS
CN Benzenamine, 3-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 221159-80-4 CAPLUS
CN Benzenamine, 3-[2-[(2S)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221159-84-8 CAPLUS
CN Benzenamine, 3-[2-[(2S)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 221159-91-7 CAPLUS
CN Benzenamine, 3-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 221159-97-3 CAPLUS
CN Benzenamine, 3-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 221160-01-6 CAPLUS
CN Benzenamine, 3-[2-[(2S)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 221160-05-0 CAPLUS
CN Benzenamine, 2-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221160-09-4 CAPLUS
CN Benzenamine, 2-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 221160-13-0 CAPLUS
CN Benzenamine, 2-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221160-22-1 CAPLUS
CN Benzenamine, 5-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-2-methoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221160-29-8 CAPLUS
CN Benzenamine, 5-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-2-methoxy-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 221160-36-7 CAPLUS
CN Benzenamine, 5-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-2-methoxy-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 221160-44-7 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[3-(4-methoxyphenyl)propyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221160-51-6 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[3-(4-methoxyphenyl)propyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 221160-58-3 CAPLUS
CN 1-Pyrrolidinepropanol, 2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-α-phenyl-, (αS,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221160-64-1 CAPLUS
CN 1-Pyrrolidinepropanol, 2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-α-phenyl-, monohydrochloride, (αS,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 221160-70-9 CAPLUS
CN 1-Pyrrolidinepropanol, 2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-α-phenyl-, (αR,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221160-75-4 CAPLUS
CN 1-Pyrrolidinepropanol, 2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-α-phenyl-, monohydrochloride, (αR,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 221160-82-3 CAPLUS
CN 1-Pyrrolidineethanol, 2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-α-[(4-methoxyphenyl)methyl]-, (αR,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221160-86-7 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-(3-phenyl-2-propenyl)-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 221160-90-3 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-(3-phenyl-2-propenyl)-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



● HCl

RN 221160-94-7 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenoxy)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221160-99-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenoxy)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 221161-03-1 CAPLUS
CN Benzenamine, 4-[3-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]propyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221161-07-5 CAPLUS
CN Benzenamine, 4-[3-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]propyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 221161-10-0 CAPLUS
CN Benzenamine, 3-[3-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]propyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221161-13-3 CAPLUS
CN Benzenamine, 3-[3-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]propyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 221161-14-4 CAPLUS
CN Benzenamine, 3-[3-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]propyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221161-15-5 CAPLUS
CN Benzenamine, 3-[3-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]propyl]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

IT **221161-19-9P 221161-20-2P 221161-21-3P**
221161-24-6P 221161-25-7P 221161-26-8P
221161-29-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of dihydrodibenzoxazepine derivs. as calcium antagonists)

RN 221161-19-9 CAPLUS

CN Carbamic acid, [4-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221161-20-2 CAPLUS

CN Carbamic acid, [4-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]phenyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA

INDEX NAME)

Absolute stereochemistry.



RN 221161-21-3 CAPLUS
CN Carbamic acid, [3-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221161-24-6 CAPLUS
CN Carbamic acid, [3-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]phenyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221161-25-7 CAPLUS
CN Carbamic acid, [3-[2-[(2S)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]phenyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221161-26-8 CAPLUS
CN Carbamic acid, [2-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221161-29-1 CAPLUS
CN Carbamic acid, [5-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-2-methoxyphenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:623166 CAPLUS
DOCUMENT NUMBER: 127:293256
TITLE: Preparation and formulation of 5,11-dihydrodibenz[b,e][1,4]oxazepine derivatives for improving the motor function of the digestive tract
INVENTOR(S): Tanaka, Yuji; Misumi, Keiji; Kawakami, Yoshinari; Moriguchi, Masahiko; Takahashi, Kazuyoshi; Okamoto, Hiroki; Kamisaki, Toshiaki; Inoue, Kimihiro; Sato, Makoto
PATENT ASSIGNEE(S): Ajinomoto, Inc., Japan
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9733885	A1	19970918	WO 1997-JP754	19970311
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9702038	A	19970917	ZA 1997-2038	19970310
TW 479057	B	20020311	TW 1997-86102931	19970310
CA 2261271	AA	19970918	CA 1997-2261271	19970311
CA 2261271	C	20030916		
AU 9722335	A1	19971001	AU 1997-22335	19970311
AU 704521	B2	19990422		
EP 889043	A1	19990107	EP 1997-905478	19970311
EP 889043	B1	20010829		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
CN 1213371	A	19990407	CN 1997-193005	19970311
CN 1085209	B	20020522		
BR 9707962	A	19990727	BR 1997-7962	19970311
JP 3127469	B2	20010122	JP 1997-532434	19970311
AT 204871	E	20010915	AT 1997-905478	19970311
ES 2159843	T3	20011016	ES 1997-905478	19970311
PT 889043	T	20020228	PT 1997-905478	19970311
NO 9804162	A	19981105	NO 1998-4162	19980910
NO 310976	B1	20010924		
US 6127361	A	20001003	US 1998-147012	19980911
US 6436922	B1	20020820	US 2000-597409	20000619
PRIORITY APPLN. INFO.:			JP 1996-83104 A	19960311
			WO 1997-JP754 W	19970311
			US 1998-147012 A1	19980911

OTHER SOURCE(S): MARPAT 127:293256
GI



I

AB The title compds. I [R1, R2 = H, halo, etc.; or R1R2 = O(CH2)nO; n = 1 - 3; R3 = H, OH; R4, R5 = H, OH; or R4R5 = O] are prepared I are calcium antagonists improving the motor function of the digestive tract. In an in vitro test for calcium antagonism using guinea pig ileum fragment, (R)-(+)-5,11-dihydro-5-[1-(4-methoxyphenethyl)-2-pyrrolidinylmethyl]dibenz[b,e][1,4]oxazepine hydrochloride (II) showed IC50 of 85 nM; in the test for calcium antagonism using rat artery fragment, II showed IC50 of 200 nM. II showed no anticholinergic activity. II gave better improvement of the motor function of the digestive tract than nicardipine. In the test for hypotensive activity, II showed ED50 of > 1000 mg/kg p.o., vs. ED50 of 4 mg/kg p.o. for nicardipine.

IT **195991-49-2P 195991-50-5P 195991-51-6P**
195991-52-7P 195991-53-8P 195991-54-9P
195991-55-0P 195991-56-1P 195991-57-2P
195991-58-3P 195991-59-4P 195991-60-7P
195991-61-8P 195991-62-9P 195991-64-1P
195991-65-2P 195991-66-3P 195991-67-4P
195991-68-5P 195991-69-6P 195991-70-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of dihydrodibenzoxazepine derivs. for improving the motor function of the digestive tract)

RN 195991-49-2 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 195991-50-5 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 195991-51-6 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[[1-[2-(4-fluorophenyl)ethyl]-2-pyrrolidinyl]methyl]-5,11-dihydro-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 195991-52-7 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[[1-[2-(4-fluorophenyl)ethyl]-2-pyrrolidinyl]methyl]-5,11-dihydro-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 195991-53-8 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[1-(2-phenylethyl)-2-pyrrolidinyl]methyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 195991-54-9 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[1-(2-phenylethyl)-2-pyrrolidinyl]methyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 195991-55-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[[1-[2-(3,4-dimethoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-5,11-dihydro-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 195991-56-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[[1-[2-(3,4-dimethoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-5,11-dihydro-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 195991-57-2 CAPLUS
CN Benzonitrile, 4-[2-[2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 195991-58-3 CAPLUS
CN Benzonitrile, 4-[2-[2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 195991-59-4 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 195991-60-7 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 195991-61-8 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[[1-[2-(3,4-dimethoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-5,11-dihydro-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 195991-62-9 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[[1-[2-(3,4-dimethoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-5,11-dihydro-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 195991-64-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[1-[2-(3-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 195991-65-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[1-[2-(3-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 195991-66-3 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[1-(2-phenylethyl)-2-pyrrolidinyl]methyl]-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 195991-67-4 CAPLUS
CN 1-Pyrrolidineethanol, 2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-α-(4-methoxyphenyl)-, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 195991-68-5 CAPLUS
CN Ethanone, 2-[2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]-1-(4-methoxyphenyl)-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 195991-69-6 CAPLUS
CN 3-Pyrrolidinol, 5-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-[2-(4-methoxyphenyl)ethyl]-, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 195991-70-9 CAPLUS
CN 3-Pyrrolidinol, 5-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-[2-(4-methoxyphenyl)ethyl]-, monohydrochloride, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

IT **195991-74-3P 195991-75-4P 195991-80-1P**
195991-81-2P 196710-93-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of dihydrodibenzoxazepine derivs. for improving the motor function of the digestive tract)

RN 195991-74-3 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[1-[2-(4-methoxyphenyl)-2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-2-pyrrolidinyl]methyl]-, (2R)-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195991-75-4 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[1-[2-(4-methoxyphenyl)-2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-2-pyrrolidinyl]methyl]-, (2S)-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195991-80-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[4-(methoxymethoxy)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, (2R-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 195991-81-2 CAPLUS
CN 3-Pyrrolidinol, 5-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-[2-(4-methoxyphenyl)ethyl]-, (3R-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 196710-93-7 CAPLUS
CN 3-Pyrrolidinol, 5-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-[2-(4-methoxyphenyl)ethyl]-, benzoate (ester), (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1996:6872 CAPLUS
DOCUMENT NUMBER: 124:105588
TITLE: Aminoacetyl Moiety as a Potential Surrogate for Diacylhydrazine Group of SC-51089, a Potent PGE2 Antagonist, and Its Analogs
AUTHOR(S): Hallinan, E. Ann; Hagen, Timothy J.; Tsymbalov, Sofya; Husa, Robert K.; Lee, Albert C.; Stapelfeld, Awilda; Savage, Michael A.
CORPORATE SOURCE: Department of Chemistry, Skokie, IL, 60077, USA
SOURCE: Journal of Medicinal Chemistry (1996), 39(2), 609-13
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB 8-Chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid, 2-[1-oxo-3-(4-pyridinyl)propyl]hydrazide, monohydrochloride (1, SC-51089) is a functional PGE2 antagonist selective for the EP1 receptor subtype with antinociceptive activity. During metabolism in cultured rat hepatocytes, SC-51089, which contains a diacylhydrazine moiety, has been shown to release hydrazine. Analogs of SC-51089, in which the diacylhydrazine functionality has been replaced by isosteric and isoelectronic groups, have been synthesized and have been shown to be analgesics and PGE2 antagonists of the EP1 subtype. This report discusses the structure-activity relationships within these series.

IT **149435-18-7P 173100-20-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and analgesic and PGE2 antagonistic activity of SC-51089 antagonists)

RN 149435-18-7 CAPLUS
CN 4-Pyridinepropanamide, N-[2-(8-chlorodibenz[b,f][1,4]oxazepin-10(11H)-yl)-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 173100-20-4 CAPLUS
CN 2-Pyridinepropanamide, N-[2-(8-chlorodibenz[b,f][1,4]oxazepin-10(11H)-yl)-2-oxoethyl]-α,α-difluoro-β-hydroxy-, monohydrochloride (9CI) (CA INDEX NAME)



L6 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1993:539280 CAPLUS
DOCUMENT NUMBER: 119:139280
TITLE: Preparation of substituted dibenzoxazepine compounds and their use as analgenic agents and prostaglandin antagonists
INVENTOR(S): Husa, Robert Knol; Hagen, Timothy Joseph; Hallinan, E. Ann
PATENT ASSIGNEE(S): G.D. Searle and Co., USA
SOURCE: Eur. Pat. Appl., 46 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 539977	A1	19930505	EP 1992-118501	19921029
R: PT				
US 5212169	A	19930518	US 1991-786161	19911031
CA 2114211	AA	19930513	CA 1992-2114211	19921002
WO 9309105	A1	19930513	WO 1992-US8217	19921002
W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
AU 9228796	A1	19930607	AU 1992-28796	19921002
EP 610303	A1	19940817	EP 1992-922137	19921002
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE				
JP 07500602	T2	19950119	JP 1992-508401	19921002
US 5288719	A	19940222	US 1993-6858	19930121
US 5382578	A	19950117	US 1993-155613	19931119
PRIORITY APPLN. INFO.:			US 1991-786161	A 19911031
			WO 1992-US8217	A 19921002
			US 1993-6858	A3 19930121

OTHER SOURCE(S): MARPAT 119:139280
GI



I

AB Title compds. I (X = NH, CH2; Y = CH2 when X = NH, NH when X = CH2; R1 = H, halo, R4O wherein R4 = H, alkyl, alkyl-, arylcarbonyl, aminobenzyl; R2 = H, halo, F3C; R3 = H, aryl, halo, heteroaryl, (alkyl)amino; Z = O, S, SO, SO2, Me3CCON, NH; m, n 0-3; p = 0, 1) or a salt thereof, are prepared 1,3-Dihydro-1,3-dioxo-2H-isoindole-2-acetic acid was converted to the acid chloride, the product refluxed with 8-chloro-10,11-dihydrodibenz[b,f][1,4]oxazepine and Et3N to give the isoindolyldibenzoxazepine derivative which in 2 steps was converted to I (X = CH2, Y = NH, R1 = R3 = H, R2 = Cl, Z = SO2, m = n = 2, p = 1) (II). II

was the most potent analgesic among the I tested.

IT **149435-18-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as analgesic and prostaglandin antagonist)

RN 149435-18-7 CAPLUS

CN 4-Pyridinepropanamide, N-[2-(8-chlorodibenz[b,f][1,4]oxazepin-10(11H)-yl)-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

=>